0GT Stock Overview
An early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Stoke Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.60 |
| 52 Week High | US$16.10 |
| 52 Week Low | US$3.40 |
| Beta | 0.95 |
| 11 Month Change | -7.02% |
| 3 Month Change | -13.11% |
| 1 Year Change | 204.60% |
| 33 Year Change | -56.56% |
| 5 Year Change | -53.10% |
| Change since IPO | -56.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -18.5% | 0.8% | -1.3% |
| 1Y | 204.6% | -17.5% | 7.4% |
Return vs Industry: 0GT exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 0GT exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 0GT volatility | |
|---|---|
| 0GT Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0GT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0GT's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 110 | Ed Kaye | www.stoketherapeutics.com |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
Stoke Therapeutics, Inc. Fundamentals Summary
| 0GT fundamental statistics | |
|---|---|
| Market cap | €571.50m |
| Earnings (TTM) | -€100.61m |
| Revenue (TTM) | €15.97m |
35.7x
P/S Ratio-5.7x
P/E RatioIs 0GT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GT income statement (TTM) | |
|---|---|
| Revenue | US$16.74m |
| Cost of Revenue | US$0 |
| Gross Profit | US$16.74m |
| Other Expenses | US$122.20m |
| Earnings | -US$105.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 100.00% |
| Net Profit Margin | -629.86% |
| Debt/Equity Ratio | 0% |
How did 0GT perform over the long term?
See historical performance and comparison